BDX vs TECH: fair value comparison
Becton, Dickinson and Company and Bio-Techne Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BDX currently sits closer to the top of our ranking by discount to fair value. TECH carries the stronger quality grade.
| BDX | TECH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $183.75 | $72.46 |
| 12-month range | $138.67–$193.76 | $43.30–$72.61 |
| Rank by discount to fair value | #38 of 108 Healthcare | #42 of 108 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BDX fair value analysis · TECH fair value analysis